This RSV Shot Keeps Babies Out of the Hospital. But Parents Can’t Find It.

February 21, 2024

3 hypodermic needles

(Wall Street Journal) – Across the U.S., parents are spending weeks and even months searching—at times without success—for Beyfortus, a new monoclonal antibody that promises to reduce drastically infants’ chances of serious illness from RSV. 

A bumpy rollout of the shot is tarnishing what otherwise promised to be a radically different RSV season, with the hunt for doses especially difficult for parents with commercial insurance. Meanwhile, the government has hundreds of thousands of doses that remain unused through a federal program reserved for at-risk children. (Read More)